SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-054966
Filing Date
2024-05-08
Accepted
2024-05-07 20:14:07
Documents
52
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q janx-20240331.htm   iXBRL 10-Q 1974438
2 EX-31.1 janx-ex31_1.htm EX-31.1 16144
3 EX-31.2 janx-ex31_2.htm EX-31.2 15261
4 EX-32.1 janx-ex32_1.htm EX-32.1 13034
  Complete submission text file 0000950170-24-054966.txt   8919583

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT janx-20240331.xsd EX-101.SCH 1021618
55 EXTRACTED XBRL INSTANCE DOCUMENT janx-20240331_htm.xml XML 2001075
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40475 | Film No.: 24923892
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)